Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16409413 | 0.91 | P2RX7 (0.49) | SMN1; SMN2P2RX7MAOANFKB1NFKB2 | |
| SCHEMBL30855164 | 0.83 | P2RX7 (0.45) | SMN1; SMN2P2RX7MAOANFKB1NFKB2 | |
| SCHEMBL29334525 | 0.83 | P2RX7 (0.45) | SMN1; SMN2P2RX7MAOANFKB1NFKB2 | |
| SCHEMBL4174627 | 0.82 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL3343887 | 0.82 | P2RX7 (0.52) | P2RX7NFKB1NFKB2RELAALDH1A1 | |
| SCHEMBL3341365 | 0.82 | P2RX7 (0.52) | P2RX7NFKB1NFKB2RELAALDH1A1 | |
| SCHEMBL4756495 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2P2RX7NFKB1NFKB2RELA | |
| SCHEMBL3159251 | 0.80 | P2RX7 (0.49) | SMN1; SMN2P2RX7 | |
| SCHEMBL20449200 | 0.80 | P2RX7 (0.49) | SMN1; SMN2P2RX7 | |
| SCHEMBL4349642 | 0.80 | P2RX7 (0.53) | P2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | SMN1; SMN2 2634/4885P2RX7 122/4885MAOA 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.